[go: up one dir, main page]

CL2019002626A1 - Anticuerpos anti-par2 y usos de los mismos. - Google Patents

Anticuerpos anti-par2 y usos de los mismos.

Info

Publication number
CL2019002626A1
CL2019002626A1 CL2019002626A CL2019002626A CL2019002626A1 CL 2019002626 A1 CL2019002626 A1 CL 2019002626A1 CL 2019002626 A CL2019002626 A CL 2019002626A CL 2019002626 A CL2019002626 A CL 2019002626A CL 2019002626 A1 CL2019002626 A1 CL 2019002626A1
Authority
CL
Chile
Prior art keywords
par2
antibodies
antigen binding
binding fragments
par2 antibodies
Prior art date
Application number
CL2019002626A
Other languages
English (en)
Inventor
Claire Dobson
Richard Williams
Ian Gurrell
Sadhana Podichetty
David Fairman
Peter Thornton
Philip Newton
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CL2019002626A1 publication Critical patent/CL2019002626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE DIVULGACIÓN PROPORCIONA ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO CAPACES DE UNIRSE A PAR2. EN ALGUNAS REALIZACIONES, LOS ANTICUERPOS ANTI-PAR2 O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS SE UNEN A PAR2 DE UNA MANERA DEPENDIENTE DEL PH. LA DIVULGACIÓN PROPORCIONA ADEMÁS MÉTODOS PARA PREPARAR Y USAR LOS ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO.
CL2019002626A 2017-03-16 2019-09-13 Anticuerpos anti-par2 y usos de los mismos. CL2019002626A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US201862637766P 2018-03-02 2018-03-02

Publications (1)

Publication Number Publication Date
CL2019002626A1 true CL2019002626A1 (es) 2019-12-06

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002626A CL2019002626A1 (es) 2017-03-16 2019-09-13 Anticuerpos anti-par2 y usos de los mismos.

Country Status (22)

Country Link
US (3) US10836822B2 (es)
EP (1) EP3596125B1 (es)
JP (3) JP7222901B2 (es)
KR (1) KR102711884B1 (es)
CN (1) CN110446720B (es)
AU (3) AU2018235031B2 (es)
BR (1) BR112019018752A2 (es)
CA (1) CA3055251A1 (es)
CL (1) CL2019002626A1 (es)
CO (1) CO2019010975A2 (es)
CR (1) CR20190417A (es)
IL (1) IL269134B2 (es)
MA (1) MA49886A (es)
MX (1) MX2019010802A (es)
NZ (1) NZ757915A (es)
PH (1) PH12019502087A1 (es)
PT (1) PT3596125T (es)
SG (1) SG11201908056QA (es)
TW (1) TWI788332B (es)
UA (1) UA125757C2 (es)
WO (1) WO2018167322A1 (es)
ZA (1) ZA201906004B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
PE20231187A1 (es) * 2020-08-18 2023-08-15 Cephalon Llc Anticuerpos anti-par-2 y metodos de uso de los mismos
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024156720A1 (en) 2023-01-25 2024-08-02 Medimmune Limited Migraine therapy
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
WO2004080373A2 (en) * 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP2380904A1 (en) * 2004-11-04 2011-10-26 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2313110A1 (en) * 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
AU2013302925B2 (en) * 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
AU2015283270B9 (en) * 2014-06-30 2021-04-01 Merck Patent Gmbh Anti-TNFa antibodies with pH-dependent antigen binding
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations

Also Published As

Publication number Publication date
CA3055251A1 (en) 2018-09-20
JP2020509762A (ja) 2020-04-02
AU2021257983A1 (en) 2021-11-25
SG11201908056QA (en) 2019-09-27
BR112019018752A2 (pt) 2020-05-05
US20230242639A1 (en) 2023-08-03
ZA201906004B (en) 2025-10-29
JP2025102812A (ja) 2025-07-08
MX2019010802A (es) 2019-10-30
CO2019010975A2 (es) 2019-10-21
KR102711884B1 (ko) 2024-10-02
WO2018167322A1 (en) 2018-09-20
CR20190417A (es) 2019-12-06
TW201843176A (zh) 2018-12-16
CN110446720A (zh) 2019-11-12
US20180305450A1 (en) 2018-10-25
US11591389B2 (en) 2023-02-28
UA125757C2 (uk) 2022-06-01
PT3596125T (pt) 2025-11-27
US10836822B2 (en) 2020-11-17
PH12019502087A1 (en) 2020-03-09
AU2018235031A1 (en) 2019-10-31
EP3596125B1 (en) 2025-11-19
AU2025203947A1 (en) 2025-06-19
JP7222901B2 (ja) 2023-02-15
CN110446720B (zh) 2023-09-12
JP2023055895A (ja) 2023-04-18
AU2018235031B2 (en) 2021-08-12
KR20190129925A (ko) 2019-11-20
AU2021257983B2 (en) 2025-02-27
IL269134B2 (en) 2024-07-01
TWI788332B (zh) 2023-01-01
US20210061905A1 (en) 2021-03-04
EP3596125A1 (en) 2020-01-22
MA49886A (fr) 2020-06-24
NZ757915A (en) 2023-05-26
IL269134A (en) 2019-11-28
IL269134B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CL2019002626A1 (es) Anticuerpos anti-par2 y usos de los mismos.
CL2018003378A1 (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
AR114002A1 (es) Anticuerpos a lilrb2
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
AR106583A1 (es) Anticuerpos que se unen específicamente a pd-1, tim-3 o pd-1 y tim-3 y sus usos
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX394121B (es) Anticuerpos que se unen a cd39 y sus usos
CL2018000458A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
MX2018009228A (es) Proteínas de unión a antigeno que se unen a pd-l1.
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2020006585A (es) Anticuerpos que se unen a ctla-4 y usos de los mismos.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
CO2017003005A2 (es) Anticuerpos anti-mfi2
EA201691650A1 (ru) Гидрофильные конъюгаты антитело-лекарственное средство
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
CR20150575A (es) Anticuerpos humanos pac1
AR104604A1 (es) ANTICUERPOS ANTI-FcRn
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.